The invention relates to a new synthesis technology of anti-
cancer drug Raltitrexed. The technology comprises the following steps: 1) using L-
glutamic acid as
raw material to perform esterification with
alcohol under the action of halogenating agent and obtain L-
glutamic acid diester
hydrochloride; 2) using 2-amino-5-methyl-
benzoic acid as
raw material to prepare 6-bromomethyl-3,4-dihydro-2-methyl-4-oxo-6-
quinazoline through cyclization,
amination and bromination; 3) using 2-thienyl-propanedioic acid as
raw material to prepare N-[5-[N-(tert-butoxycarbonyl)-N-methylamino]-2-thenoyl]-L-
glutamic acid diethyl ester through
nitrification, esterification, reduction, amino protection, N-
methylation and device-esterification; 4) using L-glutamic acid diester
hydrochloride and N-[5-[N-(tert-butoxycarbonyl)-N-methylamino]-2-thenoyl]-L-
glutamic acid diethyl ester to prepare N-[5-(N-methylamino)-2-thenoyl]-L-glutamic acid diester through dehydrant condensation and
deamination protection; and 5) using N-[5-(N-methylamino)-2-thenoyl]-L-glutamic acid diester and 6-bromomethyl-3,4-dihydro-2-methyl-4-oxo-6-
quinazoline to perform condensation under the
catalysis of alkali, recycling preparative
chromatography, purifying, and performing de-esterification to obtain Raltitrexed.